학술논문
The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study
Document Type
Article
Author
Ip, Andrew; Churnetski, Michael C; Calzada, Oscar; Chang, Andres; Liu, Yuan; Bumpers, Nassoma; Leeson, Deborah; Mahar, Ernestine; Hesaroieh, Iraj; Crain, Maria; Nooka, Ajay K; Koff, Jean L.; Hofmeister, Craig C; Gupta, Vikas A.; Allen, Pamela; Lechowicz, Mary Jo; Kaufman, Jonathan L; Blum, Kristie A.; Lonial, Sagar; Langston, Amelia; Waller, Edmund K.; Flowers, Christopher R; Cohen, Jonathon B.
Source
Blood; November 2018, Vol. 132 Issue: Supplement 1 p5911-5911, 1p
Subject
Language
ISSN
00064971; 15280020
Abstract
Calzada: Seattle Genetics: Research Funding. Nooka:Janssen pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Adaptive technologies: Consultancy, Membership on an entity's Board of Directors or advisory committees; Spectrum Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees. Hofmeister:Bristol-Myers Squibb: Research Funding; Adaptive biotechnologies: Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees. Allen:Merck: Research Funding; Bayer: Consultancy. Kaufman:Karyopharm: Other: data monitoring committee; Abbvie: Consultancy; Janssen: Consultancy; BMS: Consultancy; Roche: Consultancy. Blum:Morphosys: Research Funding; Seattle Genetics: Research Funding; Celgene: Research Funding; Novartis: Research Funding. Lonial:Amgen: Research Funding. Waller:Cambium Medical Technologies: Consultancy, Equity Ownership; Pharmacyclics: Other: Travel Expenses, EHA, Research Funding; Novartis Pharmaceuticals Corporation: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celldex: Research Funding; Kalytera: Consultancy. Flowers:Celgene: Research Funding; Millennium/Takeda: Research Funding; TG Therapeutics: Research Funding; Acerta: Research Funding; Pharmacyclics/ Janssen: Consultancy; Eastern Cooperative Oncology Group: Research Funding; V Foundation: Research Funding; Denovo Biopharma: Consultancy; Spectrum: Consultancy; Abbvie: Consultancy, Research Funding; OptumRx: Consultancy; Abbvie: Research Funding; Gilead: Research Funding; Karyopharm: Consultancy; BeiGene: Research Funding; Bayer: Consultancy; Janssen Pharmaceutical: Research Funding; Gilead: Consultancy; Genentech/Roche: Research Funding; Pharmacyclics: Research Funding; National Cancer Institute: Research Funding; Burroughs Wellcome Fund: Research Funding; Genentech/Roche: Consultancy. Cohen:Bristol-Myers Squibb: Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Research Funding; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; BioInvent: Consultancy; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Infinity Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Research Funding; Infinity Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Millennium: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Millennium: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; BioInvent: Consultancy; Pharmacyclics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Research Funding.